26 March 2024
UK to launch carbon border adjustment mechanism (CBAM) in 2027
1 min read
On 21 March 2024, the UK Government launched additional consultation on the introduction of a UK carbon border adjustment mechanism (UK CBAM) from January 2027.
On 21 March 2024, the UK Government launched additional consultation on the introduction of a UK carbon border adjustment mechanism (UK CBAM) from January 2027. The consultation is open for comments until 13 June 2024.
The consultation document prepared by HM Revenue & Customs and HM Treasury provides useful information about the possible design and administration of the UK CBAM. While at first sight the UK CBAM may look quite similar to the EU CBAM, there are some important differences between the two mechanisms.
Our latest Client Alert has more information on the topic.
Attachments:
->
News & insights
1 min
read
read
Briefings
VBB secures lowest anti-dumping duty for Hankook in EU passenger car tyre investigation
7 July 2026
2 min
read
read
Briefings
Lithuanian Competition Authority Fines Pharmacy Association and Individual Firms for Collusion while Participating in Margin-setting Procedure
14 December 2022
2 min
read
read
Briefings
France - Supreme Court Allows Follow-on Damages Action by Health Insurer in Wake of Sanofi’s Denigration Strategy against Generic Rivals
13 October 2023
2 min
read
read
Briefings
European Commission Sends Statement of Objections to Teva over Abusive Patent Filings and Disparagement of Generic Competitors
11 October 2022
1 min
read
read
Briefings
F. Hoffmann-La Roche and Novartis (Avastin - Lucentis) – ECJ Finds Concerted Efforts to Restrict Off-label Use of Medicinal Products Likely to Breach Competition Rules
24 January 2018
3 min
read
read
Briefings
Advocate General Recommends to Court of Justice of European Union to Allow Reimbursement of Off Label Use of Medicine for Purely Budgetary Reasons
30 August 2018
3 min
read
read
Briefings
“National Healthcare Insurance Systems Are Allowed To Reimburse Off-Label Use of Medicine” Says ECJ
21 November 2018
3 min
read
read
Briefings
French Competition Authority - Genentech, Novartis and Roche Fined EUR 444 million in Saga Involving Wet Age-Related Macular Degeneration
9 September 2020
